{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T16:08:22Z","timestamp":1776960502168,"version":"3.51.4"},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Mortality in coronavirus disease of 2019 (COVID-19) is associated with increases in prothrombotic parameters, particularly D-dimer levels. Anticoagulation has been proposed as therapy to decrease mortality, often adjusted for illness severity.<\/jats:p><jats:p>\n          Objective\u2003We wanted to investigate whether anticoagulation improves survival in COVID-19 and if this improvement in survival is associated with disease severity.<\/jats:p><jats:p>\n          Methods\u2003This is a cohort study simulating an intention-to-treat clinical trial, by analyzing the effect on mortality of anticoagulation therapy chosen in the first 48\u2009hours of hospitalization. We analyzed 3,625 COVID-19+ inpatients, controlling for age, gender, glomerular filtration rate, oxygen saturation, ventilation requirement, intensive care unit admission, and time period, all determined during the first 48\u2009hours.<\/jats:p><jats:p>\n          Results\u2003Adjusted logistic regression analyses demonstrated a significant decrease in mortality with prophylactic use of apixaban (odds ratio [OR] 0.46, p\u2009=\u20090.001) and enoxaparin (OR\u2009=\u20090.49, p\u2009=\u20090.001). Therapeutic apixaban was also associated with decreased mortality (OR 0.57, p\u2009=\u20090.006) but was not more beneficial than prophylactic use when analyzed over the entire cohort or within D-dimer stratified categories. Higher D-dimer levels were associated with increased mortality (p\u2009&lt;\u20090.0001). When adjusted for these same comorbidities within D-dimer strata, patients with D-dimer levels\u2009&lt;\u20091 \u00b5g\/mL did not appear to benefit from anticoagulation while patients with D-dimer levels\u2009&gt;\u200910 \u00b5g\/mL derived the most benefit. There was no increase in transfusion requirement with any of the anticoagulants used.<\/jats:p><jats:p>\n          Conclusion\u2003We conclude that COVID-19+ patients with moderate or severe illness benefit from anticoagulation and that apixaban has similar efficacy to enoxaparin in decreasing mortality in this disease.<\/jats:p>","DOI":"10.1055\/s-0040-1720978","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T23:46:25Z","timestamp":1605311185000},"page":"1691-1699","source":"Crossref","is-referenced-by-count":133,"title":["Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality"],"prefix":"10.1055","volume":"120","author":[{"given":"Henny H.","family":"Billett","sequence":"additional","affiliation":[{"name":"Division of Hematology, Departments of Oncology and Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morayma","family":"Reyes-Gil","sequence":"additional","affiliation":[{"name":"Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0202-7058","authenticated-orcid":false,"given":"James","family":"Szymanski","sequence":"additional","affiliation":[{"name":"Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ikemura","sequence":"additional","affiliation":[{"name":"Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay R.","family":"Stahl","sequence":"additional","affiliation":[{"name":"Montefiore Information Technology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yungtai","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Population Health and Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shafia","family":"Rahman","sequence":"additional","affiliation":[{"name":"Division of Hematology, Departments of Oncology and Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus D.","family":"Gonzalez-Lugo","sequence":"additional","affiliation":[{"name":"Division of Hematology, Departments of Oncology and Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Kushnir","sequence":"additional","affiliation":[{"name":"Division of Hematology, Departments of Oncology and Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Barouqa","sequence":"additional","affiliation":[{"name":"Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ladan","family":"Golestaneh","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eran","family":"Bellin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Population Health and Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"N Chen","year":"2020","journal-title":"Lancet"},{"issue":"08","key":"ref2","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/jth.14888","article-title":"Incidence of venous thromboembolism in hospitalized patients with COVID-19","volume":"18","author":"S Middeldorp","year":"2020","journal-title":"J Thromb Haemost"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","article-title":"Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy","volume":"191","author":"C Lodigiani","year":"2020","journal-title":"Thromb Res"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00134-020-06062-x","article-title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study","volume":"46","author":"J Helms","year":"2020","journal-title":"Intensive Care Med"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3892\/etm.2013.1466","article-title":"Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: a prospective clinical study","volume":"7","author":"X L Liu","year":"2014","journal-title":"Exp Ther Med"},{"issue":"23","key":"ref6","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation","volume":"135","author":"J M Connors","year":"2020","journal-title":"Blood"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"N Tang","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00277-020-04216-x","article-title":"Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York City hospital experience","volume":"99","author":"A Hanif","year":"2020","journal-title":"Ann Hematol"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2020.05.001","article-title":"Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19","volume":"76","author":"I Paranjpe","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"08","key":"ref10","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1097\/ACM.0b013e3181df0f3b","article-title":"Democratizing information creation from health care data for quality improvement, research, and education-the Montefiore Medical Center Experience","volume":"85","author":"E Bellin","year":"2010","journal-title":"Acad Med"},{"key":"ref11","volume-title":"Missing Management: Health-Care Analytic Discovery in a Learning Health System","author":"E Bellin","year":"2019"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/jth.14869","article-title":"High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients","volume":"18","author":"J F Llitjos","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/jth.14821","article-title":"The versatile heparin in COVID-19","volume":"18","author":"J Thachil","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref14","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/jth.14146","article-title":"Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study","volume":"16","author":"K P Cohoon","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref15","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"A A Khorana","year":"2019","journal-title":"N Engl J Med"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.avsg.2012.06.010","article-title":"Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin","volume":"27","author":"RdeA Yoshida","year":"2013","journal-title":"Ann Vasc Surg"},{"issue":"08","key":"ref17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"M Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1177\/0003319719840861","article-title":"Nonhemostatic activities of factor Xa: are there pleiotropic effects of anti-FXa direct oral anticoagulants?","volume":"70","author":"S Papadaki","year":"2019","journal-title":"Angiology"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11239-020-02123-6","article-title":"Role of rivaroxaban in sunitinib-induced renal injuries via inhibition of oxidative stress-induced apoptosis and inflammation through the tissue necrosis factor-\u03b1 induced nuclear factor-\u03baappa B signaling pathway in rats","volume":"50","author":"N O Al-Harbi","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"m1966","DOI":"10.1136\/bmj.m1966","article-title":"Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study","volume":"369","author":"C M Petrilli","year":"2020","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.cca.2020.06.051","article-title":"Time-dependent changes in the clinical characteristics and prognosis of hospitalized COVID-19 patients in Wuhan, China: a retrospective study","volume":"510","author":"M Wang","year":"2020","journal-title":"Clin Chim Acta"},{"issue":"09","key":"ref24","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1111\/jth.15004","article-title":"ISTH DIC subcommittee communication on anticoagulation in COVID-19","volume":"18","author":"J Thachil","year":"2020","journal-title":"J Thromb Haemost"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1720978.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T23:49:44Z","timestamp":1608767384000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1720978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,23]]},"published-print":{"date-parts":[[2020,12]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1720978","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,13]]}}}